Newsfile Corp
28 May 2026, 22:45 UTC · 20h ago
Source · https://www.newsfilecorp.com/release/299279/ALDX-SHAREHOLDER-NOTICE-Faruqi-Faruqi-LLP-Reminds-Aldeyra-Therapeutics-ALDX-Investors-of-Securities-Class-Action-Deadline-on-May-29-2026
Read source
Story key points
3 claims · impact-rated
The FDA issued a Complete Response Letter rejecting Aldeyra's NDA for reproxalap due to insufficient evidence of efficacy. — The rejection of a primary drug candidate by the FDA is a catastrophic fundamental failure for a biotech company.
-1.00Aldeyra's stock price plummeted 70.7% to $1.24 per share following the FDA's rejection of reproxalap. — This confirms a massive loss of market capitalization and a severe shift in investor sentiment.
-0.80A federal securities class action lawsuit has been filed against Aldeyra alleging that executives made false or misleading statements regarding reproxalap clinical trials. — Legal liabilities and class action lawsuits create additional financial overhang and reputational risk.
-0.40Ticker attribution
Model heads
Continue reading
6 related stories
Search tags
FDA rejected the company's NDA for reproxalap, leading to a massive stock price drop and a securities class action lawsuit.
The company is the subject of a securities class action lawsuit deadline notice.
The company is the subject of a securities class action lawsuit deadline notice.
No ticker relationship head found.
Impact vectors
1 dimensions · 9 clusters
Market reaction
0 bid · 10 offered
No stock impact ranking available yet.
